Fed. Circ. Rules Teva's Copaxone Patents Are Invalid
The Federal Circuit on Friday affirmed decisions by a Delaware federal judge and the Patent Trial and Appeal Board that patents on Teva's blockbuster multiple sclerosis drug Copaxone are invalid, a...To view the full article, register now.
Already a subscriber? Click here to view full article